Fig. 4From: Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysisRisk difference in the incidence of ≥ grade 3 AEs between patients who received IRI- and Ox-based regimens. IRI, irinotecan; Ox, oxaliplatinBack to article page